FI Investors Have Opportunity to Lead Fiserv, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Investors who purchased the Company's securities between July 24, 2024 and July 22, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before September 22, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Fiserv forced merchants using its Payeezy platform to migrant to the Clover program due to cost issues and other problems. The Company's Clover platform revenue growth was unsustainably boosted by these conversions. The Company lost customers to competitors due to Clover's high prices and poor customer service. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Fiserv, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Revvity Inc (RVTY) Q2 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ...
Revenue: $720 million in Q2, 3% organic growth. Adjusted EPS: $1.18, above expectations. Life Sciences Segment Growth: 4% organic growth. Diagnostics Segment Growth: 2% organic growth. Signals Software Growth: Over 30% organic growth. Free Cash Flow: $115 million in Q2, 83% conversion of adjusted net income. Operating Margin: 26.6% adjusted operating margin, down 210 basis points year over year. Share Repurchase: $293 million worth of shares repurchased in Q2. Full-Year Organic Growth Outlook: 2% to 4% range. Full-Year Adjusted EPS Outlook: $4.85 to $4.95. Net-Debt-to-Adjusted-EBITDA Ratio: 2.6 times. Adjusted Tax Rate: 19.1% in Q2. Warning! GuruFocus has detected 5 Warning Signs with RVTY. Release Date: July 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revvity Inc (NYSE:RVTY) achieved 3% organic growth in Q2 2025, in line with expectations, driven by strong performance in the Life Sciences segment. The Signals Software franchise experienced approximately 30% growth, setting a new record for orders in a single quarter. Revvity Inc (NYSE:RVTY) reported adjusted EPS of $1.18, which was above expectations and guidance. The company generated $115 million in free cash flow during the quarter, maintaining a solid 90% conversion rate year-to-date. Revvity Inc (NYSE:RVTY) repurchased nearly $300 million worth of stock in Q2, bringing total repurchases to nearly $450 million for the first half of the year. Negative Points The Diagnostics segment faced challenges in China due to changes in hospital lab reimbursement policies, impacting the Immunodiagnostics business. Revvity Inc (NYSE:RVTY) lowered its full-year organic growth outlook to 2% to 4%, down 1% from prior expectations. The company anticipates a meaningful pullback in its Immunodiagnostics business in China for the remainder of the year. Operating margins were pressured by lower volumes of high-margin diagnostic tests and recent changes in FX rates. The academic and government customer segment continued to show weakness, with revenue declining in the low single digits year over year. Q & A Highlights Q: Can you explain the guidance change related to organic growth, particularly in China, and whether other factors like VBP are involved? A: (Prahlad Singh, CEO) The majority of the impact is from the DRG policy in China, which affects multiplex tests. This policy reduces test volumes, but in the long term, it may lead to more single-plex tests, which are more expensive. We are working with stakeholders to potentially reverse these changes due to their impact on patient care. Q: Regarding margin changes, what are your expectations for 2026 margins, and what growth assumptions are they based on? A: (Maxwell Krakowiak, CFO) We expect a baseline operating margin of 28% for 2026, with margin expansion depending on organic growth levels. Typically, with high single-digit growth, we expect a 75 basis point margin expansion, and with mid-single-digit growth, about 50 basis points. Q: What are the revenue pacing assumptions for this year, and how do you see the impact of NIH funding and year-end budget flush? A: (Maxwell Krakowiak, CFO) We expect normal seasonality with a high single-digit ramp in both Life Sciences and Diagnostics. The fourth quarter will see a ramp-up in gel and larger volume in Signals Software. We assume academic and government funding will remain weak for the rest of the year. Q: Can you provide insights into the Life Sciences segment's performance, particularly reagents and instruments, and any guidance changes? A: (Prahlad Singh, CEO) Pharma-biotech showed stability with mid-single-digit growth, and our Life Sciences reagents business has grown for five consecutive quarters. While capital equipment spending is impacted, we remain optimistic about the reagents business. Q: How is the Software segment performing, and what are the expectations for growth in the second half? A: (Prahlad Singh, CEO) The Signals Software business had a record quarter with 32% organic growth. We focus on net retention, ARR, and APV, with strong SaaS bookings. We expect continued growth due to investments and new product launches. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
43 minutes ago
- Business Insider
Walmart Stock (WMT) Widening Gap on Rivals Despite Holiday Price Hikes Ahead
Shares in U.S. retail giant Walmart (WMT) were marked higher today as it said it expects to gain market share from tariff turmoil this year. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Market Share According to a note from analysts at Jefferies, even though Walmart has already raised prices on a range of goods given the uncertainty around President Trump's tariffs, it still expects to gain market share from its peers. Following a recent meeting with Walmart's head of investor relations, Steph Wissink, Jefferies said in a note that 'prices increased as the tariffs were implemented in April' for perishables and other items sourced from Central America. The firm noted that in June, prices also began to rise on 'infrequently purchased general merchandise items that were previously trending deflationary.' Such macro risks are key for consumer-facing stocks like Walmart as one can see below. Value Focus Jefferies said Walmart (NYSE:WMT) expects further increases on 'seasonal items heading into Halloween and the winter holidays,' but remains committed to its value-focused strategy: 'WMT remains committed to its Everyday Low Price strategy and taking less price than its peers,' it said. Despite inflationary pressures, Jefferies said Walmart believes that the U.S. consumer has been relatively resilient. 'We would categorize the US consumer as consistent,' said Jefferies, though Walmart has seen 'emerging signs of trade down and substitution.' It is understood that Walmart plans to aggressively compete during the upcoming back-to-school season by 'widening its price gaps on key, high-frequency items,' which it expects will boost share as consumers become more price-sensitive. Walmart is already performing well against its peers as can be seen below. In terms of inventory, Jefferies said Walmart expects it to jump in the second quarter given that the 'actual tariff rate is higher than originally expected.' However, analysts said they are 'not concerned about the health of the inventory.' Jefferies expects the company to reaffirm its full-year outlook, stating, 'We believe that WMT is well-positioned to achieve its guidance,' even as tariff-related volatility limits near-term upside. Jefferies has a Buy rating on the stock and a $120 price target. Is WMT a Good Stock to Buy Now? On TipRanks, WMT has a Strong Buy consensus based on 28 Buy ratings. Its highest price target is $120. WMT stock's consensus price target is $111.33, implying a 14.06% upside.
Yahoo
44 minutes ago
- Yahoo
How The J. M. Smucker Company (SJM) Fits into the Food Dividend Stock Portfolio
The J. M. Smucker Company (NYSE:SJM) is included among the 10 Best Food Stocks with Dividends. A wholesaler distributing peanut butter, fruit spreads and specialty spreads to a retailer. The J. M. Smucker Company (NYSE:SJM) is recognized as a strong value in the food sector, with several successful brands under its belt. Notable performers include pet food lines like Meow Mix and Milk-Bone, as well as the well-liked Uncrustables sandwich products. The company paid a premium when it acquired Hostess Brands in November 2023. To refocus its efforts, the company recently sold off some brands from its Sweet Baked Snack segment, including Voortman, to concentrate more on the Hostess portfolio. Although the transition has been challenging, The J. M. Smucker Company (NYSE:SJM) appears to be moving in the right direction. It anticipates full-year fiscal 2026 sales to grow by 2% to 4%, despite the effects of divesting certain Sweet Baked Snack value brands. The company is also expected to deliver strong earnings and free cash flow. In fiscal Q4 2025, The J. M. Smucker Company (NYSE:SJM) reported operating cash flow of $393.9 million, and its free cash flow was $298.9 million. During the quarter, the company returned $114.5 million to shareholders through dividends, reinforcing its commitment to investor return. This cash position enables the company to consistently raise its dividends. The J. M. Smucker Company (NYSE:SJM) declared a 1.9% hike in its quarterly dividend on July 16. This marked the company's 24th consecutive year of dividend growth, which makes it one of the best food stocks with dividends. The company now offers a quarterly dividend of $1.10 per share and has a dividend yield of 4.04%, as of July 27. While we acknowledge the potential of SJM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: READ NEXT: and Disclosure: None. 登入存取你的投資組合
